Health Care [ 2/12 ] | Biotechnology [ 19/74 ]
NASDAQ | Common Stock
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States.
The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.
It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction.
In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials.
Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 5, 26 | -1.67 Decreased by -22.79% | -1.65 Decreased by -1.21% |
| Feb 24, 26 | -1.50 Decreased by -19.05% | -1.56 Increased by +3.85% |
| Nov 5, 25 | -1.54 Decreased by -13.24% | -1.59 Increased by +3.14% |
| Aug 7, 25 | -1.12 Increased by +14.50% | -1.34 Increased by +16.42% |
| May 6, 25 | -1.36 Decreased by -2.26% | -1.36 |
| Feb 25, 25 | -1.26 Increased by +8.70% | -1.17 Decreased by -7.33% |
| Nov 6, 24 | -1.36 Decreased by -0.74% | -1.24 Decreased by -9.68% |
| Aug 8, 24 | -1.31 Increased by +2.24% | -0.91 Decreased by -43.96% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 19.36 M Increased by +1.13 K% | -206.03 M Decreased by -27.67% | Decreased by -1.06 K% Increased by +89.58% |
| Dec 31, 25 | 17.75 M Increased by +4.89% | -183.03 M Decreased by -22.00% | Decreased by -1.03 K% Decreased by -16.31% |
| Sep 30, 25 | 1.94 M Increased by +318.14% | -306.18 M Decreased by -90.71% | Decreased by -15.81 K% Increased by +54.39% |
| Jun 30, 25 | 66.77 M Increased by +26.71 K% | -134.37 M Increased by +6.24% | Decreased by -201.25% Increased by +99.65% |
| Mar 31, 25 | 1.58 M Increased by +89.10% | -161.38 M Decreased by -18.97% | Decreased by -10.22 K% Increased by +37.09% |
| Dec 31, 24 | 16.93 M Increased by +912.38% | -150.02 M Decreased by -9.59% | Decreased by -886.28% Increased by +89.18% |
| Sep 30, 24 | 463.00 K Increased by +22.49% | -160.54 M Decreased by -24.05% | Decreased by -34.67 K% Decreased by -1.27% |
| Jun 30, 24 | 249.00 K Decreased by -71.28% | -143.32 M Decreased by -11.41% | Decreased by -57.56 K% Decreased by -287.93% |